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ABSTRACT 
Background 
In Scotland, a national HPV immunisation programme began in 2008 for 12-13 year 
olds, with a catch-up campaign from 2008-2011 for those under the age of 18. To 
monitor the impact of HPV immunisation on cervical disease at the population level, a 
programme of national surveillance was established. 
Methods 
We analysed colposcopy data from a cohort of women born between 1988-1992 who 
entered the Scottish Cervical Screening Programme (SCSP) and were aged 20-21 in 
2008-2012. 
Results 
By linking datasets from the SCSP and colposcopy services, we observed a significant 
reduction in diagnoses of cervical intraepithelial neoplasia 1 (CIN 1) (RR 0.71, 95% 
CI 0.58 to 0.87, p=0.0008), CIN 2 (RR 0.5, 95% CI 0.4, 0.63, p<0.0001) and CIN 3 
(RR 0.45, 95% CI 0.35 to 0.58, p< 0.0001) for women who received 3 doses of 
vaccine compared with unvaccinated women. 
Conclusions 
To our knowledge, this is one of the first studies to show a reduction of low and high 
grade cervical intraepithelial neoplasia associated with high uptake of the HPV 
bivalent vaccine at the population level.  These data are very encouraging for 
countries that have achieved high HPV vaccine uptake. 
 
Keywords: human papillomavirus; vaccine; cervical intraepithelial neoplasia 
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INTRODUCTION 
In the UK, cervical cancer is the second most common cancer in women under 
35 years (Cancer Research UK, 2010). Human papillomavirus (HPV) types 16 and 18 
are known to be essential for the development of at least 70% of cervical cancers 
(Smith et al, 2007) but may contribute in excess of 80% of cervical cancers in 
Scotland (Cuschieri et al, 2010). The prophylactic bivalent vaccine prevents infection 
with HPV types 16 and 18 and has been shown to induce strong and sustained 
neutralising antibody responses which prevent cervical HPV 16 and 18 infection and 
confer protection against consequent viral-induced cervical intraepithelial neoplasia 
(CIN) (Paavonen et al, 2009). The vaccine may also afford immunological cross-
protection against other high-risk oncogenic HPV types which are phylogenetically 
related to HPV 16 and 18, including HPV 31, 33 and 45 (Malagon et al, 2012; 
Kavanagh et al, 2014).  
The quadrivalent HPV vaccine has been provided in Australia through the 
national HPV vaccination programme since April 2007. Early indications from the 
HPV vaccination programme suggest that there has been a decrease in high-grade 
cervical cytological abnormalities (HGA coded as CIN of grade 2 or worse or CGIN) 
of the cervix in girls younger than 18 years (Brotherton et al, 2011). Although the 
study did not directly link pathology results with immunisation status, it provided 
evidence that high uptake of the HPV vaccine (approximately 70%) was temporally 
correlated with a decrease in cervical cancer precursors at the population level. 
Since 2008, school-based uptake of bivalent HPV vaccine
 
in girls aged 12-13 
in Scotland has been impressive, with vaccine uptake sustained at levels >90% (NHS 
Information Services Division, 2011; Sinka et al, 2014). Furthermore, a three-year 
(from September 2008 to 2011) catch-up campaign offered vaccination to all girls 
aged 13 to 17, with uptake recorded at between 80% and 30% in younger and older 
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girls at age of vaccination respectively (NHS Information Services Division, 2012). In 
order to estimate vaccine impact it is important to ascertain the effect of the 
vaccination programme on the whole population, with particular focus on the age 
group where these changes will be initially observed. In Scotland cervical screening is 
offered 3-yearly to all women aged 20 to 60 years. Therefore it is one of the few 
countries in the world able to detect an early impact of the vaccine through 
population-based surveillance. 
Scotland has a population of 5.2 million and almost all care is provided by the 
National Health Service (NHS). Preventive health programmes operate population 
registers based on birth and patient care registration systems with a common unique 
person identifier. One of the major strengths of Scottish health data is the ability to 
perform robust data linkage in a national population, using Community Health Index 
(CHI) (Bhopal et al, 2012). In this study we have used such linkage to complete 
preliminary analysis of the impact of the bivalent vaccine on HPV-associated disease 
at the population level. These attributes allow us to demonstrate early impact of high 
HPV immunisation coverage to show significant reductions in the diagnosis of low 
and high grade CIN level.  
  
METHODS 
HPV surveillance cohorts. 
As part of the Health Protection Scotland (HPS) HPV surveillance strategy, 
cohorts of young women born between 1988 and 1992 were assessed to determine 
vaccine impact. The study identification number and the patient Community 
Health Index reference (CHI, a unique national patient identifier) were sent to  
Information Services Division (ISD) of the National Health Service (NHS) in 
Scotland, who used CHI to link the national Scottish Immunisation call Recall System 
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(SIRS) and Child Health Schools Programme-System (CHSP-S) data to screening and 
colposcopy attendance. This is described more fully elsewhere (Kavanagh et al., 
2014). 
The range of ages spans the period of eligibility for vaccination (1990-1992 
i.e. the catch-up cohort) and also provides mainly unvaccinated individuals (1988 and 
1989) from the early cohorts, for comparison. Geographical data-zone (Scottish 
Government, 2005) derived from the postcode of residence, was attributed to each 
record allowing assignment of the Scottish Index of Multiple Deprivation (SIMD) 
(Scottish Government) to each individual in the cohorts. 
Vaccination status derived from Child Health Schools Programme-System 
(CHSP-S) or the Scottish Immunisation Recall System (SIRS) which act as the call 
and recall register for immunisation programmes in Scotland is linked to all 
individuals in the cohort.  
 
Data linkage of the cohort. 
 Women are referred directly by the Scottish Cervical Call and Recall System 
(SCCRS) to colposcopy for further investigation on the basis of high grade 
dyskaryosis, repeat low grade dykaryosis or borderline nuclear abnormality (BNA).  
Colposcopy data are collected routinely for all referred individuals in NHS Scotland 
via the National Colposcopy Clinical Information and Audit System (NCCIAS).  This 
information is episode based and comprises patient demographics, appointment 
details, clinical data including referral, clinical signs and symptoms, colposcopy 
assessment and findings, biopsy results, cytology results, treatments and the follow-up 
care management plan.  
NHS Information Services Division (ISD) provided an extract of this data to 
HPS, matching NCCIAS patients to the HPV surveillance cohort via an anonymous 
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reference number.  Extracts from NCCIAS are received by HPS on a quarterly basis, 
with the data in this study based on linked referrals to the end of May 2013.  
 
Statistical analysis. 
We restricted our analysis to those individuals in the cohort with a cervical 
screening attendance date in SCCRS after the age of eligibility (age 20). In the 
NCCIAS dataset, individuals may have more than one linked histological episode to 
the index referral cytology. We restricted our analysis to the incident abnormal 
histological episode.  Incidence rates  per 1000 person-year were calculated by 
comparing the number of cases of each diagnosis to the number of individuals 
screened, adjusting for the person-time contribution of each individual as those born 
in the early cohorts have more time to develop an outcome. This contribution was 
calculated as the number of months between the individual attending for their first 
screen and the date of referral for the incident abnormal histological episode if present 
(which could occur following a later screening attendance, or alternatively to 31
st
 May 
2013 (the latest month for which referrals were extracted), whichever occurred first. 
Incidence rates per 1000 person year were stratified by vaccination status and birth 
cohort. 
The relative risk of CIN in the vaccinated population compared to the 
unvaccinated population was calculated using Poisson regression adjusting for cohort 
year to model potential changes in sociological behaviour which may exist from one 
birth cohort to the next, deprivation score (assessed via the SIMD quintiles of the area 
of residence where 1 is most deprived and 5 is least deprived) and age. Person-time 
contribution was used as an offset. Individuals were censored at the date of referral for 
an incident abnormal histological episode (all grades) or the 31
st
 May 2013. As the 
risk of an abnormal histological episode may change over time, age is included as a 
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time dependent co-variate, with person-time contribution and the number of abnormal 
histological episodes stratified by the age of the individual in months as they move 
through the study.  For each grade of CIN, interaction tests were carried out to 
consider differences in the vaccine effect between cohort years and between 
deprivation (SIMD quintile).  
 As a sensitivity analysis, we considered only the abnormal histological 
episodes which followed the first cervical screen in only those who attended for 
screening at age 20 or 21.  The odds of CIN in the vaccinated population compared to 
the unvaccinated population were then calculated using logistic regression adjusting 
for cohort year and deprivation score for grades CIN 1, 2 and 3 individually.  This 
analysis considers a more homogeneous population in terms of age and attendance for 
screening, and age at histological examination.  All statistical analysis was conducted 
in R version 3.0.3 (R Development 2014). 
 
RESULTS 
 
Cohort analysis. 
Across all 5 birth cohorts (n=200867), 53.5% (n=106052) attended for their 
first cervical screen at age 20 or above (Table 1).  Attendance was lowest for the 
youngest cohort i.e. those born in 1992 (36.3%) with these individuals having less 
follow-up time at screening attendance, at the time of data extraction.  Across all 5 
cohorts, 72% were unvaccinated and 24% received 3 doses of vaccination, with 
vaccine uptake varying significantly by cohort year.  99% of those born in 1988 and 
1989 were unvaccinated since the programme was not targeted at these individuals.  A 
proportion of those born in 1990 and all of those born in 1991 and 1992 were eligible 
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for vaccination.  Vaccine uptake increased yearly and was highest for the 1992 cohort 
where 74% of individuals received 3 doses (Table 1).   
The first result for an abnormal referral (this includes a result of CIN 1 or 
worse) occurring after the date of first screen for each individual was considered.  
Those with a date of referral prior to the date of first screen were excluded (n=10), 
reducing the total cohort size from 106052 to 106042. Of the 10 excluded individuals, 
five individuals had CIN1 and were all unvaccinated, four individuals had CIN2, three 
of whom were unvaccinated and one individual had CIN 3 who was unvaccinated.  In 
total there were 4854 abnormal histology (CIN 1-3) episodes; 1753 were CIN 1, 1698 
CIN2 and 1403 CIN3 (Table 1).  
 
Incidence and relative risk of CIN 1, 2 and 3. 
Incidence rates for CIN 1, 2 and 3 diagnosis per 1000 person year by number 
of vaccinations received and birth cohort were estimated (Figure 1). For those fully 
vaccinated in 1990-1992, there is a clear reduction in incidence of CIN 3 between 
unvaccinated and fully vaccinated individuals e.g. in 1991, the incidence in the 
unvaccinated is 7.93 per 1000 person years (p1000py) (95% CI: 6.13, 10.10) 
compared to 3.66 p1000py (95% CI: 2.80, 4.69) in those receiving 3 doses.  This 
reduction in incidence of CIN 3 was statistically significant in both the unadjusted and 
adjusted models (3 dose unadjusted RR 0.59, 95% CI: 0.48, 0.72, p<0.0001; 3 dose 
adjusted RR 0.45, 95% CI:  0.35, 0.58, p<0.0001) (Table 2).  Although those 
receiving 2 doses of vaccine had a lower incidence rate of CIN 3 than the 
unvaccinated group in the 1990-1992 cohorts, the adjusted relative risk was not 
statistically significant (2 dose adjusted RR 0.77, 95% CI:  0.49, 1.21, p=0.25). 
The adjusted analysis (Table 2) also showed a statistically significant 
difference in relative risk of diagnoses of CIN 2 (RR 0.5, 95% CI 0.4, 0.63, p<0.0001) 
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and CIN 1 (RR 0.71, 95% CI 0.58, 0.870, p= 0.0008) associated with 3 doses of 
vaccine compared with those who were unvaccinated. Two doses of vaccine were 
associated with a reduced risk of both CIN 2 and CIN 1 but this was not statistically 
significant (CIN 2: RR 0.81, 95% CI 0.54, 1.22, p= 0.32 and CIN 1: RR 0.65, 95% CI 
0.42, 1.01, p= 0.056). 
Relative risk of CIN 1, 2 and 3 diagnosis was significantly lower for the least 
deprived women (SIMD 5) compared to the most deprived (SIMD 1), even when 
differences in vaccination were accounted for (Table 2). For each outcome, the 
relative risk of a diagnosis was significantly lower among women from affluent areas 
compared to women from very deprived areas.  
Table 2 also shows that there was a significant reduction in all grades of CIN 
in those born in 1989. Furthermore, for CIN3 there are significant reductions in those 
born in the 1989 and 1992 cohorts but not in those born in 1990 and 1991.  Generally 
the trend is downwards and conducting a test for linear trend shows that for each of 
CIN 1, 2 and 3 there is a significant linear change over the cohort years (p=0.0126; 
p<0.0001 and p=0.0009 respectively). 
There was no significant interaction between the number of vaccine doses and 
deprivation (SIMD score) on occurrence of CIN 1, 2 or 3 (p-value of interaction tests 
p=0.65, p=0.811 and p=0.63 respectively) nor between the number of vaccine doses 
and the birth cohorts (p-value of interaction tests p=0.48, p=0.1 and p=0.86 
respectively). 
 
Sensitivity analysis. 
We conducted a sensitivity analysis of only those individuals screened at age 
20 or 21 and consider only incident abnormal histology occurring within 6 months of 
their first screen. This reduced our total cohort size to 91677 of which 73% were 
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unvaccinated and 23% fully vaccinated.  Within this reduced cohort, there were 602 
CIN 1, 617 CIN 2 and 575 CIN 3 diagnoses.  In adjusted analyses, women vaccinated 
with 3 doses had a statistically significant reduced risk of being diagnosed with CIN 
1, 2 and 3 (Table 3), similar to that observed in the age-adjusted model (table 2) 
although the confidence intervals were wider due to the smaller cohort size. As in the 
full model, 2 doses of vaccine was associated with a reduction in each of CIN 1, 2 and 
3 but this was not statistically significant (p=0.176, p=0.121, p=0.352 respectively).  
In this analysis, there was no significant change in the numbers of CIN 1 and 2 
by cohort year (p-values of the linear test of trend were 0.497and 0.4463 
respectively).  For CIN 3, there was evidence of a linear trend (p= 0.044) driven by 
the large reduction in the 1992 cohort coupled with marginal reductions in the 
preceding birth cohorts. 
 
DISCUSSION 
 In this study, we have completed a preliminary analysis of the impact of the 
bivalent vaccine on HPV-associated cervical disease at the population level. To our 
knowledge, this is the first population-based study to report a statistically significant 
decrease in incidence of cervical intra-epithelial neoplasia grades 1, 2 and 3 (29%, 
50% and 55% respectively) in women aged 20-21, associated with three doses of 
bivalent HPV vaccine administered during a catch-up campaign.  
 The vaccinated women in this cohort received the HPV vaccine through a 
national catch-up campaign, with mean uptake across all age groups for all 3 doses 
recorded as 66% (NHS Information Services Division, 2012). Since 2008, the uptake 
rate of the HPV vaccine in the routine cohort (immunised at age 12 to 13 years) has 
consistently achieved > 90% (NHS Information Services Division, 2011)
 
and 
therefore any effect on HPV-associated disease is likely to be even more profound 
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than that observed in the catch-up cohort. These data are very encouraging for 
countries that have achieved high HPV vaccine uptake. 
Long-term surveillance of the effects of HPV vaccination in the population 
commenced in Scotland in 2008 and incorporates the study of both HPV prevalence in 
residual liquid-based cytology samples from screening (Kavanagh et al, 2013), and 
the monitoring of HPV-associated disease through national screening and colposcopy 
services. Preliminary analysis of HPV prevalence in the Scottish catch-up cohort 
corroborates previous studies (Paavonen et al, 2009; Wheeler et al, 2012)
 
and shows 
that the bivalent vaccine is strongly associated with a reduction in both HPV 16 and 
18, while affording cross-protection against HPV 31, 33 and 45 (Kavanagh et al, 
2014) .  
Our analysis focused on the risk of CIN 1, 2 and 3 dependent on the number of 
doses of vaccine received adjusted for cohort year, deprivation and age at observation. 
Cohort year is used to model the possible background patterns of changes in 
sociological behaviour which may exist from one birth cohort to the next. This may 
influence the levels of CIN 1, 2 and 3 observed i.e. those born in 1988 have two 
invitations to be screened and 3 years of opportunistic screening between those 
periods while those people born in 1989 will not have the same screening 
opportunities, hence the reduction in all grades of CIN in the 1989 cohort. In the 
sensitivity analyses, which considered a more homogeneous population, there was no 
significant change in the numbers of CIN 1 and 2 by cohort year. 
Although there was a significant reduction in all grades of CIN associated with 
3 doses of vaccine in this cohort, no statistically significant reduction was observed in 
individuals who were partially immunised. However, almost all of the women who 
received two doses of vaccine in this cohort were immunised at 0 and 1 month. 
Further data are required to assess what protective effect is afforded by <3 doses of 
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vaccine since only 3.8% of women in our cohort were partially vaccinated. We hope 
to elucidate the long-term efficacy of a 2-dose vaccine regimen through the analysis 
of updated quarterly colposcopy extracts to the national surveillance programme since 
studies suggest a 2-dose regimen may be both protective and cost-effective 
(Romanowski et al, 2011; Kreimer et al, 2011)
 
. 
HPV vaccination and regular cervical screening offers the best combination 
for prevention of cervical cancer. However, knowledge and awareness of HPV 
infection, cervical cancer and screening in young girls who have been vaccinated 
against the virus, is surprisingly low (Bowyer et al, 2013). This has prompted 
concerns that those girls who have been vaccinated may not realise they still require 
regular cervical screening (Marlow et al, 2007; Henderson et al, 2011). Reassuringly, 
we found that there was no reduction in the initial uptake of cervical screening in 
those women who were born in 1990 and had been vaccinated in the catch-up cohort. 
Nevertheless, it is imperative that health education initiatives continue to emphasise 
the importance of attendance at cervical screening for vaccinated women. This is 
especially important, given the association of increased levels of HPV positivity and 
poor attendance at cervical screening with increased deprivation 2¶/HDU\et al, 2011; 
Baker & Middleton, 2003). 
One of the main limitations with attributing reductions in CIN to vaccination 
is that women born in 1991 and 1992 who were fully vaccinated, would likely have 
been at school up to the age of 18 while the majority of the unvaccinated women in 
these cohorts would likely have left school at age 16.  Coupled with this is the 
observation from a baseline prevalence study prior to vaccination that the levels of 
HPV positivity among girls aged 16-18 who had left school was much higher 
compared to those who were still at school 2¶/HDU\et al, 2011). Thus the 
comparison of fully vaccinated with unvaccinated cohorts is confounded with leaving 
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school, but no individual adjustment can be made for this with the data available in 
this study. Attributing the reduction in severe disease solely to vaccination will over-
estimate the impact of the vaccination but given that this study reports a 55% 
reduction in the relative risk of CIN 3 associated with 3 doses of vaccine, it is 
extremely unlikely that all of this effect is confounded with leaving school early.  
Our work builds upon previous studies which assessed high-grade 
abnormalities and CIN data in both vaccinated and unvaccinated individuals, 
respectively (Kavanagh et al, 2014; Powell et al, 2012; Crowe et al, 2014; Baldur-
Felskov et al, 2014). To our knowledge, this is the first study to report vaccine 
effectiveness findings against cervical lesions for the bivalent vaccine in a population 
rather than in a trial setting. The strengths of our analyses are that we have a largely 
complete population-based dataset on cervical screening that we can then directly link 
to disease and vaccination status through use of our national databases. Scotland is 
therefore in a strong position to assess the ongoing impact of the HPV vaccine on 
HPV-associated disease in the years ahead, including assessment in 2015 of vaccine 
impact in the routinely immunised girls. These data are generalisable to countries that 
have achieved high HPV vaccine uptake such as Australia, Portugal and Rwanda 
(Hopkins & Wood, 2013).  This study highlights the gains that can be achieved if 
action is taken to overcome recognised barriers to high vaccine uptake. 
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Cohort 
Year 
Attendance at cervical screening 
at age 20 or greater % of screened population immunised 
Number of cervical 
abnormalities amongst those 
screened 
N 
screened 
N total % 
screened 
Unvaccinated 1 dose 2 doses 3 doses CIN 1 CIN 2 CIN 3 
1988 26021 41948 62.00% 99.95% 0.01% 0.01% 0.03% 638 670 559 
1989 22168 40618 54.60% 99.66% 0.12% 0.07% 0.15% 449 474 378 
1990 23124 39377 58.72% 82.29% 1.41% 2.63% 13.67% 375 320 276 
1991 20510 39672 51.70% 31.03% 3.02% 6.70% 59.24% 217 175 151 
1992 14229 39252 36.30% 18.45% 2.41% 5.06% 74.08% 74 59 39 
TOTAL 106052* 200867 52.70% 71.77% 1.24% 2.57% 24.42% 1753 1698 1403 
 
*reduces to 106042 when remove those with referral dates prior to first recorded screening date.  This removed 5 CIN1 (all unvaccinated), 4 CIN 2 
(3 unvaccinated, 1 fully-vaccinated) and 1 CIN3 (unvaccinated) ± CIN figures in table are with these exclusions. 
 
Table 1:  Breakdown of each birth cohort in terms of number screened and the proportion vaccinated against HPV 16 and 18 (n=106052) and the 
number of cervical abnormalities (CIN 1-3) found in the follow-up period (to 31
st
 May 2013).
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RR 95% CI p-value RR 95% CI p-value RR 95% CI p-value RR 95% CI p-value RR 95% CI p-value RR 95% CI p-value
CIN 1 CIN 2 CIN 3
Unvaccinated 1 1 1 1 1 1
1 dose 1.33 (0.81, 2.18) 0.253 0.98 (0.59, 1.63) 0.9491 1.31 (0.8, 2.15) 0.277 1.03 (0.62, 1.71) 0.9182 1.89 (1.2, 2.97) 0.0061 1.42 (0.89, 2.28) 0.1445
2 doses 0.9 (0.59, 1.37) 0.632 0.65 (0.42, 1.01) 0.0557 1.05 (0.71, 1.55) 0.8 0.81 (0.54, 1.22) 0.3203 1.03 (0.67, 1.58) 0.9064 0.77 (0.49, 1.21) 0.25
3 doses 1 (0.87, 1.16) 0.962 0.71 (0.58, 0.87) 0.0008 0.64 (0.54, 0.77) <0.0001 0.5 (0.40, 0.63) <0.0001 0.59 (0.48, 0.72) <0.0001 0.45 (0.35, 0.58) <0.0001
1988 1 - 1 - 1 - 1 -
1989 1 (0.89, 1.13) 0.9531 0.86 (0.76, 0.97) 0.0184 1.01 (0.9, 1.14) 0.872 0.86 (0.76, 0.97) 0.0167 0.95 (0.84, 1.09) 0.489 0.84 (0.73, 0.96) 0.0098
1990 1.18 (1.04, 1.34) 0.0112 0.93 (0.81, 1.07) 0.2852 0.95 (0.83, 1.09) 0.479 0.78 (0.67, 0.90) 0.0005 1.01 (0.87, 1.16) 0.923 0.89 (0.76, 1.04) 0.1488
1991 1.18 (1.01, 1.38) 0.0379 0.82 (0.67, 1.01) 0.061 0.89 (0.75, 1.06) 0.189 0.74 (0.59, 0.91) 0.0052 0.94 (0.78, 1.13) 0.508 0.86 (0.68, 1.08) 0.2034
1992 1.3 (1.03, 1.66) 0.0306 0.66 (0.50, 0.89) 0.0059 0.98 (0.75, 1.28) 0.902 0.58 (0.42, 0.79) 0.0006 0.78 (0.57, 1.08) 0.139 0.49 (0.34, 0.71) 0.0002
SIMD 1 1 - 1 - 1 - 1 -
SIMD 2 0.83 (0.72, 0.95) 0.0087 0.84 (0.73, 0.96) 0.0112 0.83 (0.72, 0.94) 0.0041 0.84 (0.73, 0.95) 0.0071 0.94 (0.82, 1.08) 0.386 0.95 (0.83, 1.10) 0.4922
SIMD 3 0.83 (0.72, 0.96) 0.011 0.84 (0.73, 0.97) 0.0174 0.67 (0.58, 0.78) <0.0001 0.69 (0.60, 0.80) <0.0001 0.64 (0.54, 0.75) <0.0001 0.66 (0.56, 0.77) <0.0001
SIMD 4 0.8 (0.69, 0.93) 0.0035 0.82 (0.70, 0.94) 0.0066 0.62 (0.53, 0.72) <0.0001 0.64 (0.55, 0.74) <0.0001 0.59 (0.5, 0.7) <0.0001 0.61 (0.52, 0.73) <0.0001
SIMD 5 0.74 (0.64, 0.86) 0.0001 0.76 (0.66, 0.88) 0.0002 0.45 (0.39, 0.53) <0.0001 0.47 (0.40, 0.56) <0.0001 0.45 (0.38, 0.54) <0.0001 0.47 (0.40, 0.57) <0.0001
Adjusted* estimatesUnadjusted estimates Adjusted* estimates Unadjusted estimates Adjusted* estimates Unadjusted estimates
 
 Table 2:  Unadjusted and adjusted estimates of the relative risk of CIN 1, 2 and 3 by number of vaccinations. *adjusted for cohort year, SIMD and age in months 
(time dependent covariate ± not shown) 
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OR 95% CI p-value OR 95% CI p-value OR 95% CI p-value
CIN 1 CIN 2 CIN 3
Unvaccinated 1 - Unvaccinated 1 - Unvaccinated 1 -
1 dose 0.92 (0.45, 1.88) 0.8046 0.64 (0.28, 1.45) 0.276 1.91 (1.11, 3.29) 0.0193
2 doses 0.66 (0.36, 1.20) 0.1765 0.62 (0.34, 1.13) 0.1216 0.75 (0.41, 1.36) 0.3524
3 doses 0.59 (0.44, 0.79) 0.0006 0.4 (0.29, 0.55) <0.0001 0.5 (0.36, 0.69) <0.0001
1988 1 - 1 - 1 -
1989 1 (0.80, 1.25) 0.9760 0.89 (0.72, 1.11) 0.2976 0.78 (0.62, 0.98) 0.0332
1990 0.91 (0.72, 1.16) 0.4567 0.85 (0.68, 1.06) 0.1552 0.92 (0.74, 1.15) 0.4744
1991 1.04 (0.77, 1.39) 0.8160 0.98 (0.73, 1.31) 0.8894 0.85 (0.63, 1.15) 0.2807
1992 1.14 (0.78, 1.67) 0.4737 0.79 (0.52, 1.21) 0.2809 0.56 (0.35, 0.89) 0.0143
SIMD 1 1 - 1 - 1 -
SIMD 2 0.65 (0.51, 0.83) 0.0005 0.77 (0.62, 0.95) 0.0183 0.83 (0.66, 1.03) 0.095
SIMD 3 0.71 (0.56, 0.91) 0.0074 0.53 (0.41, 0.68) <0.0001 0.6 (0.47, 0.78) <0.0001
SIMD 4 0.74 (0.58, 0.94) 0.0181 0.57 (0.44, 0.73) <0.0001 0.59 (0.46, 0.77) <0.0001
SIMD 5 0.66 (0.52, 0.84) 0.0013 0.37 (0.28, 0.49) <0.0001 0.33 (0.24, 0.46) <0.0001
 
Table 3:  Adjusted odds of CIN 1, 2 and 3 in the 6 months following the date of screening in those attending screening at age 20 or 21 who have 6 months of 
follow-up available 
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Figure 1: Incidence rates per 1000 person year (p1000py) and associated 95% confidence intervals of CIN 1, 2 and 3 stratified by birth cohort and 
vaccination status (unvaccinated versus fully vaccinated with 3 doses) 
 
 
